- MorphoSys AG MOR announced preliminary results from the ongoing Phase 1/2 study of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers.
- The data showed responses or disease stabilization in five cohorts with evaluable patients.
- Four out of ten evaluable patients with ovarian clear cell carcinoma had a partial response, and three had stable disease.
- Five of eight evaluable patients with metastatic castration-resistant prostate cancer had stable disease.
- Two of the four evaluable patients with endometrial carcinoma had partial responses, one of whom later achieved a complete response after data cutoff, and two had stable disease.
- Two of the three evaluable patients with peripheral T-cell lymphoma had complete responses. There were two partial responses and four disease stabilizations for the nine evaluable patients with mesothelioma.
- The safety profile of tulmimetostat was consistent with the mechanism of action of EZH2 inhibition.
- The company also presented updated results from the Phase 1 dose-escalation portion of the trial, in which 41 patients were treated with oral tulmimetostat ranging from 50 mg to 375 mg daily.
- One dose-limiting toxicity of grade 4 thrombocytopenia was observed, which occurred at the highest dose.
- The disease control rate at 375 mg was 66.7%. Disease control was noted across doses except at 137.5 mg.
- Three of six patients in the 100 mg cohort had disease stabilization.
- Four of the seven patients in the 225 mg cohort had disease stabilization, and one with BAP-1 mutated mesothelioma had a partial response.
- Another partial response was noted in ARID1A-mutated endometrial carcinoma at 375 mg.
- Price Action: MOR shares are down 8.45% at $4.66 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
